

Rahul Singhvi

Dr. Rahul Singhvi is a business leader in the vaccine and pharmaceutical industry. He is Managing Partner and co-Founder of MLV Healthcare Partners (MLVHCP), a New York based merchant bank. Prior to cofounding MLVHCP, Dr. Singhvi served as the President & CEO of Novavax, Inc, a NASDAQ listed, development stage biotechnology company. During his tenure at Novavax, he transformed Novavax from a distressed specialty pharmaceutical company into a premier vaccine development company. Under his leadership, Novavax's valuation rose from \$35M to almost \$300M and enjoyed a robust pipeline of important clinical and preclinical stage vaccine candidates, including those against influenza, respiratory syncytial virus (RSV), and other infectious diseases. At Novavax, Dr. Singhvi developed a non-dilutive financing strategy through partnerships with governments and international companies. These partnerships included a major contract with the United States government agency HHS-BARDA worth over \$179MM that was critical for Novavax to finance its pandemic and seasonal flu vaccines through late stage clinical development. Other key partnerships included those with GE Healthcare (manufacturing), LG Life Sciences (Korea), Cadila Pharmaceuticals Limited (India) and Avimex (Mexico). In addition, Dr. Singhvi raised over \$100 million for Novavax through multiple equity financings. Prior to joining Novavax in 2005, Dr. Singhvi served in a number of positions at Merck & Co., where he helped develop several vaccines, including Zostavax®, the only vaccine on the market to prevent shingles.

Dr. Singhvi was named one of the most influential Marylanders in the healthcare field by The Daily Record in 2010. During the same year, Novavax was named one of the ten most innovative companies in the biotechnology industry by Fast Company magazine. Dr. Singhvi has served as a member of the Clinton Global Initiative and currently serves on the Board of Directors of Immunocellular Therapeutics (OTCBB: IMUC), a US public company working on cancer vaccines. Dr. Singhvi graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his M.S. and Sc.D degrees in chemical engineering from MIT. He also received an MBA

degree from the Wharton School of the University of Pennsylvania where he graduated as a Palmer Scholar.